Key Message
Evidence of limited quality from two studies of oral cannabidiol in combination with other antiepileptic drugs indicated that cannabidiol may increase serum levels of clobazam. One of these two studies also found that oral cannabidiol may increase serum levels of eslicarbazepine, topiramate, zonisamide, and rufinamide. This evidence was limited by a high risk of bias and may not be generalizable to the Canadian context. Additionally, only antiepileptic drugs were studied. No evidence-based guidelines surrounding drug interactions with medical cannabis were found.